Dr. Krumdieck studies a range of conditions that affect the blood and immune system. He works with patients suffering from B-cell non-Hodgkin's lymphoma, a type of cancer, exploring how they respond to treatments like ibritumomab tiuxetan. He also investigates genetic conditions such as C6 deficiency, which increases the risk of severe infections, especially meningitis. Additionally, his research touches on the immune system’s regulation, particularly how substances like decorin can affect immune responses in autoimmune diseases. Dr. Krumdieck's work is vital in improving diagnosis and management strategies for these conditions.
Key findings
In a study of 18 lymphoma patients, 89% responded positively to the first treatment with ibritumomab tiuxetan, while 77% showed a positive response after retreatment, with manageable side effects occurring in 28% to 44% of patients.
Research into C6 deficiency identified specific genetic mutations in individuals, aiding in better diagnoses and treatment strategies for those susceptible to severe infections.
Decorin was shown to decrease the activity of the immune complex C1 by about 50%, suggesting its potential role in regulating immune responses, particularly in autoimmune diseases.
In a case report of a woman with Waldenström's macroglobulinemia, factor XIII deficiency was linked to an acquired inhibitor caused by isoniazid, and subsequent treatments were necessary to manage her bleeding disorder.
Frequently asked questions
Does Dr. Krumdieck study lymphoma?
Yes, he researches treatments for B-cell non-Hodgkin's lymphoma, focusing on patient responses to retreatment options.
What specific condition is linked to C6 deficiency?
C6 deficiency, a rare genetic condition, makes individuals more susceptible to severe infections like meningitis, which Dr. Krumdieck studies.
Has Dr. Krumdieck researched immune system disorders?
Yes, he has studied how substances like decorin can regulate immune responses, particularly in autoimmune diseases.
Is Dr. Krumdieck's work relevant for patients with bleeding disorders?
Absolutely, he has investigated cases like factor XIII deficiency associated with Waldenström's macroglobulinemia and the impact of medications on bleeding issues.
Publications in plain English
Retreatment with yttrium-90 ibritumomab tiuxetan in patients with B-cell non-Hodgkin's lymphoma.
2007
Leukemia & lymphoma
Shah J, Wang W, Harrough VD, Saville W, Meredith R +17 more
Plain English This study focused on patients with B-cell non-Hodgkin's lymphoma who received a second round of treatment with a drug called ibritumomab tiuxetan. Researchers looked at 18 patients, finding that after the first treatment, 89% responded positively, while after the second treatment, 77% responded, with manageable side effects like low blood cell counts occurring in 28% to 44% of patients. These findings indicate that many patients can safely receive this treatment again and still experience benefits, which is important for improving their outcomes.
Who this helps: This helps patients with B-cell non-Hodgkin's lymphoma.
Molecular bases for inherited human complement component C6 deficiency in two unrelated individuals.
1996
Journal of immunology (Baltimore, Md. : 1950)
Nishizaka H, Horiuchi T, Zhu ZB, Fukumori Y, Nagasawa K +7 more
Plain English The study focused on two individuals with a rare condition called C6 deficiency, which can make them more susceptible to severe infections, particularly meningitis. Researchers found specific genetic mutations in both cases: one had a deletion in part of their C6 gene that created a faulty protein, while the other had a different deletion and an unidentified mutation. Understanding these genetic issues is important because it helps in diagnosing and managing the health risks associated with C6 deficiency.
Who this helps: This information benefits patients with C6 deficiency and their doctors by improving diagnosis and treatment options.
The proteoglycan decorin binds C1q and inhibits the activity of the C1 complex.
1992
Journal of immunology (Baltimore, Md. : 1950)
Krumdieck R, Höök M, Rosenberg LC, Volanakis JE
Plain English This study looked at a substance called decorin, which is found in various tissues, to understand how it interacts with a part of the immune system known as the C1 complex. The researchers found that decorin can attach to a component called C1q and reduce the activity of the C1 complex by about 50% when there is enough decorin present. This is important because it shows that decorin can potentially regulate immune responses, which could be beneficial in conditions where the immune system is overactive or misbehaving.
Who this helps: This helps patients with autoimmune diseases or other conditions related to immune system dysfunction.
Plain English This study focused on a 75-year-old woman who developed bleeding issues while taking a medication called isoniazid for tuberculosis. She had a large abdominal bruise and tests showed she had a problem with a blood-clotting factor called factor XIII due to an inhibitor in her blood. After stopping the medication, treatments like plasma exchange helped reduce the inhibitor, but infusions of factor XIII were necessary to restore her ability to form clots properly.
Who this helps: This helps patients with bleeding disorders linked to medications, especially those with underlying conditions like Waldenström's macroglobulinemia.
New methods for the study of folate coenzymes: endogenous polyglutamate patterns of subcellular hepatocyte fractions and of regenerating rat liver.
1983
Advances in experimental medicine and biology
Krumdieck CL, Eto I, Krumdieck R
Plain English This study looked at different types of folate (a type of vitamin B) found in liver cells of rats to understand how these substances are organized and how they change in response to liver regeneration. Researchers found that there are three main groups of folate, with one group making up about 44% of total folates, another about 37%, and the last one around 19%. After the liver was partially removed and began to regrow, the amounts of certain forms of folate changed significantly, indicating that the length of folate chains is linked to how the body processes one-carbon compounds.
Who this helps: This research benefits doctors and researchers by providing insights into how liver function and folate metabolism are connected.